Skip to main content

Table 2 Outcomes for placeo controlled trials in bipolar depression [18, 20, 22] – efficacy and discontinuations in trials lasting 8 weeks

From: Atypical antipsychotics in bipolar disorder: systematic review of randomised trials

   Events/total patients Event rate (%)   
Outcome Trials Treatment Placebo Treatment Placebo Relative Risk (95% CI) NNT (95% CI)
Efficacy        
Response        
olanzapine 2–20 mg/day 1 137/351 108/355 39 30 1.3 (1.04 to 1.6) 11.6 (6.4 to 62)
quetiapine 300–600 mg/day 2 379/648 313/330 58 40 1.5 (1.3 to 1.7) 5.4 (4.2 to 7.7)
Combined atypical 3 516/999 240/685 52 35 1.4 (1.2 to 1.6) 6.0 (4.8 to 7.7)
Symptomatic remission        
olanzapine 2–20 mg/day 1 115/351 87/355 33 25 1.3 (1.06 to 1.7) 12.1 (6.7 to 62)
quetiapine 300–600 mg/day 2 640/648 96/330 52 29 1.8 (1.5 to 2.2) 4.3 (3.5 to 5.9)
Combined atypical 3 455/999 183/685 46 27 1.6 (1.3 to 1.9) 5.3 (4.3 to 7.0)
Emergence of mania        
olanzapine 2–20 mg/day 1 19/345 23/345 6 7 0.8 (0.5 to 1.5) not calculated
quetiapine 300–600 mg/day 2 23/697 18/347 5 3 0.6 (0.4 to 1.2) not calculated
Combined atypical 3 42/1042 41/692 4 6 0.7 (0.5 to 1.1) not calculated
Discontinuations        
All cause        
olanzapine 2–20 mg/day 1 191/351 232/355 54 65 0.8 (0.7 to 0.9) 9.1 (5.5 to 27)
quetiapine 300–600 mg/day 2 292/702 132/349 38 42 1.1 (0.8 to 1.3) not calculated
Combined atypical 3 483/1053 364/704 46 52 0.9 (0.8 to 1.05) 17 (10 to 50)
Lack of efficacy        
olanzapine 2–20 mg/day 1 73/351 121/355 21 34 0.6 (0.5 to 0.8) 7.5 (5.1 to 15)
quetiapine 300–600 mg/day 2 13/702 37/349 2 11 0.2 (0.1 to 0.3) 11 (7.7 to 20)
Combined atypical 3 86/1053 158/704 8 22 0.5 (0.4 to 0.6) 7.0 (5.6 to 10)
Adverse events        
olanzapine 2–20 mg/day 1 34/351 19/355 10 5 1.8 (1.1 to 3.1) 23 (12 to 220)
quetiapine 300–600 mg/day 2 109/702 17/349 16 5 3.2 (2.0 to 5.2) 9.4 (6.7 to 14)
Combined atypical 3 143/1053 36/704 14 5 2.6 (1.8 to 3.7) 12 (10 to 14)
  1. For discontinuations NNTp is shown in bold, indicating fewer events with treatment than placebo. More events with treatment than placebo, NNH, is in plain text. The trial with olanzapine included only the monotherapy treatment arm